Generate Biomedicines Caps Strong Month for Biotech IPOs with $400M Offering
February 26, 2026
Generate Biomedicines raised $400 million in its initial public offering, selling 25 million shares at $16 each. Shares began trading under the ticker "GENB," making it the biotech sector's largest IPO by total proceeds since Acelyrin's $540 million offering in May 2023.
The AI drug discovery company, co-founded through Flagship Pioneering by TJHSST alum Geoffrey von Maltzahn, had already raised over $800 million in venture capital and secured approximately $110 million in payments from collaborations with Amgen and Novartis. The IPO proceeds will fund pivotal Phase 3 trials of its lead candidate, GB-0895, an AI-designed anti-TSLP antibody for severe asthma.
Including Generate, five biotechs raised nearly $1.4 billion in February 2026 IPO proceeds, making it the most active month for new biotech stock offerings in over a year.